Drug recall · November 8, 2023
Bisoprolol Fumarate and Hydrochlorothiazide Tablets recall
Why: Failed Impurities/Degradation Specifications
Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).
The recall
- Product
Bisoprolol Fumarate and Hydrochlorothiazide Tablets, USP, 5mg/6.25mg, 100-count Bottle, RX only, Manufactured by: Glenmark Pharmaceuticals Limited, Pithampur, Madhya Pradesh 454775, India, Manufactured for: Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430. NDC 68462-879-01
- Lots / codes
Lot# 17212352, Exp 11/31/2023
- Quantity
- 480 100-count bottles
- Company
- Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ
- Distribution
- Nationwide in the USA
- Initiated
- October 20, 2023 · Voluntary: Firm initiated
- Classified
- November 2, 2023
- Reported
- November 8, 2023
- Ended
- August 16, 2024
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Bisoprolol / hydrochlorothiazide
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.